Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122521) titled 'A Study on the Efficacy and Safety of AG Sequential NAL-IRI plus 5-FU/LV with or without Camrelizumab in the Conversion Therapy for Locally Advanced Pancreatic Cancer' on April 14.
Study Type: Interventional study
Study Design:
Non randomized control
Primary Sponsor: Shanghai General Hospital
Condition:
Locally Advanced Pancreatic Cancer
Intervention:
Arm 2: Sequential combination therapy with camrelizumab:AG Sequential NAL-IRI, 5-FU/LV Combined with Camrelizumab
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-04-15
Target Sample Size: Arm 2: Sequential combination therap...